Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies - Episode 3
When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis
Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.
Video series above is prompted by the following:
- Are there scenarios where comprehensive testing might be unnecessary or less practical (certain tumor types)?
- In which scenarios might you prefer narrow panel testing over comprehensive testing?
Related Content:
